Genenta Science S.p.A. (NASDAQ:GNTA) Short Interest Down 26.5% in February

Genenta Science S.p.A. (NASDAQ:GNTA) was the target of a significant drop in short interest in the month of February. As of February 15th, there was short interest totalling 2,500 shares, a drop of 26.5% from the January 31st total of 3,400 shares. Based on an average trading volume of 10,500 shares, the short-interest ratio is currently 0.2 days.

Institutional Trading of Genenta Science

A hedge fund recently bought a new stake in Genenta Science stock. Citadel Advisors LLC acquired a new stake in shares of Genenta Science S.p.A. (NASDAQ:GNTA) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm acquired 11,167 shares of the company’s stock, valued at approximately $46,000. Citadel Advisors LLC owned 0.06% of Genenta Science at the end of the most recent reporting period. Hedge funds and other institutional investors own 15.13% of the company’s stock.

Genenta Science Trading Down 2.3 %

GNTA opened at $3.90 on Monday. Genenta Science has a 1-year low of $2.20 and a 1-year high of $7.28. The firm’s 50 day simple moving average is $4.22 and its two-hundred day simple moving average is $4.57.

About Genenta Science

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.